Sugi Predict

Sugi Predict / Targets / XBP1

XBP1

X-box-binding protein 1 · P17861 · XBP1 on Sugi Atlas →

88,520 patent compounds predicted against XBP1, 57,844 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Helenalin Helenalin (SCHEMBL161593) 1.00 4/20
Helenalin Helenalin (SCHEMBL161594) 1.00 4/20
SCHEMBL212369 SCHEMBL212369 0.49 4/20
SCHEMBL213134 SCHEMBL213134 0.49 4/20
SCHEMBL212961 SCHEMBL212961 0.47 4/20
SCHEMBL213177 SCHEMBL213177 0.47 4/20
SCHEMBL213424 SCHEMBL213424 0.47 4/20
SCHEMBL213624 SCHEMBL213624 0.47 4/20
SCHEMBL215250 SCHEMBL215250 0.47 4/20
SCHEMBL212968 SCHEMBL212968 0.47 4/20
SCHEMBL212829 SCHEMBL212829 0.44 4/20
SCHEMBL213778 SCHEMBL213778 0.42 4/20
SCHEMBL212157 SCHEMBL212157 0.41 4/20
SCHEMBL212158 SCHEMBL212158 0.41 4/20
SCHEMBL79357 SCHEMBL79357 0.40 3/20
SCHEMBL243754 SCHEMBL243754 0.69 2/20
SCHEMBL64277 SCHEMBL64277 0.66 2/20
SCHEMBL116925 SCHEMBL116925 0.66 2/20
SCHEMBL70106 SCHEMBL70106 0.64 2/20
SCHEMBL70211 SCHEMBL70211 0.64 2/20

Clinical trials — most relevant to XBP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin PHASE2/PHASE3UNKNOWN
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection PHASE2COMPLETED
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer PHASE1/PHASE2COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Quantification of GADD34 Expression in RA nanCOMPLETED
Effect of Protein on Endoplasmic Reticulum Stress nanNOT_YET_RECRUITING
Periodontal Status and Endothelial Dysfunction in Patients With Polycystic Ovary Syndrome nanCOMPLETED
Effect of Non-chirurgical Periodontal Treatment on the Immune System From a Gender Perspective nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Involvement of Pollutants in Atopic Dermatitis and Psoriasis nanUNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients nanUNKNOWN
GADD34 and Type I IFN Response Genes in SLE nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
I-Tracking Neurodegeneration in Early Wolfram Syndrome nanCOMPLETED
Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis nanNOT_YET_RECRUITING
Mitoquines in COPD nanUNKNOWN
Tecfidera Diffusion Tensor Imaging nanCOMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） nanRECRUITING
Nasturtium (Tropaeolum Majus L) Intake and Biochemical Parameters in Pre-diabetic Subjects in Bogota Colombia nanCOMPLETED
Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients nanNOT_YET_RECRUITING
Tracking Neurodegeneration in Early Wolfram Syndrome nanCOMPLETED
Study of the Sex Differences in Inflammatory Diseases in Children nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a XBP1 binder may also engage these)

ProteinNameSimilarity
Q3SZZ2 — 1.000 Q3SZZ2 →
O35426 — 0.996 O35426 →
Q9R1S4 — 0.995 Q9R1S4 →
Q2M1V0 — 0.978 Q2M1V0 →
Q9BUA3 — 0.976 Q9BUA3 →
Q8N1L9 — 0.976 Q8N1L9 →
Q9UFD9 — 0.976 Q9UFD9 →
Q9Y2Y4 — 0.975 Q9Y2Y4 →
Q3UIZ8 — 0.974 Q3UIZ8 →
Q3LU41 — 0.974 Q3LU41 →
Q80W88 — 0.974 Q80W88 →
Q8R1H8 — 0.974 Q8R1H8 →
Q9ERS8 — 0.973 Q9ERS8 →
E1BE02 — 0.973 E1BE02 →
Q8N5Z5 — 0.973 Q8N5Z5 →
O08686 — 0.973 O08686 →
Q9UMQ3 — 0.973 Q9UMQ3 →
Q8TAB5 — 0.973 Q8TAB5 →
Q8IX15 — 0.972 Q8IX15 →
P70178 — 0.972 P70178 →
Q8BP99 — 0.972 Q8BP99 →
Q75NR7 — 0.972 Q75NR7 →
Q8N1G0 — 0.972 Q8N1G0 →
Q5RJB0 — 0.972 Q5RJB0 →
Q9D2D7 — 0.972 Q9D2D7 →
A6NNA5 — 0.972 A6NNA5 →
P0C6A0 — 0.972 P0C6A0 →
Q2MHN3 — 0.972 Q2MHN3 →
A4GTP4 — 0.972 A4GTP4 →
Q0GGX2 — 0.971 Q0GGX2 →